Ken Griffin Gain Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$3.21 - $5.04 $13,161 - $20,664	4,100 Added 273.33%	5,600 $21,000
Q4 2023 Feb 14, 2024	SELL	$2.07 - $3.4 $413 - $680	-200 Reduced 11.76%	1,500 $4,000
Q3 2023 Nov 14, 2023	SELL	$3.19 - $4.68 $48,488 - $71,136	-15,200 Reduced 89.94%	1,700 $5,000
Q2 2023 Aug 14, 2023	BUY	$4.36 - $5.5 $17,876 - $22,550	4,100 Added 32.03%	16,900 $75,000
Q1 2023 May 15, 2023	BUY	$3.18 - $5.16 $40,704 - $66,048	12,800 New	12,800 $61,000

2.58M

22.2K

16K

Ticker GANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,883,400
Market Cap $15.2M
Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.